Zobrazeno 1 - 10
of 72
pro vyhledávání: '"George J. Knight"'
Autor:
George J. Knight, Glenn E. Palomaki, Geralyn Lambert-Messerlian, Robert G. Best, Edward R. Ashwood
Publikováno v:
Genetics in Medicine. 17:897-900
We sought to determine whether tests for fetal aneuploidy based on next-generation sequencing of cell-free DNA in maternal circulation have had an impact on routine serum-based screening in the general pregnant population. We compared results from la
Comparing Three Screening Strategies for Combining First- and Second-Trimester Down Syndrome Markers
Publikováno v:
Obstetrics & Gynecology. 107:367-375
OBJECTIVE: To describe the choices and tradeoffs inherent in 3 published strategies that combine first- and second-trimester markers for Down syndrome screening. METHODS: Published marker distributions for Down syndrome and unaffected pregnancies in
Autor:
Christian Meier, Louis M. Neveux, Anne Summers, Glenn E. Palomaki, James E. Haddow, Tianhua Huang, Andrea O'Donnell, George J. Knight, David Wright
Publikováno v:
Prenatal Diagnosis. 26:730-739
Objectives To confirm that measuring pregnancy-associated plasma protein-A (PAPP-A) in both first- and second-trimester serum samples improves Down syndrome screening. Methods We selected paired first- and second-trimester stored serum samples from 3
Publikováno v:
Clinical Chemistry. 50:1804-1808
Background: Approximately two million pregnancies in the United States are screened for Down syndrome annually by use of second-trimester maternal serum markers. At present, a combination of four markers can identify 75% of affected pregnancies when
Autor:
Charles M. Strom, George C. Cunningham, Glenn E. Palomaki, George J. Knight, Marie Roberson, Raj Pandian, Jo Ellen Lee
Publikováno v:
Clinical Chemistry. 50:182-189
Background: Down syndrome screening is commonly performed in the US using maternal age and three or four second-trimester maternal serum markers that can identify up to 75% of affected pregnancies by offering diagnostic studies to 5% of women. Invasi
Autor:
Wayne A. Miller, Glenn E. Palomaki, George J. Knight, James E. Haddow, Anthony L. Johnson, Josephine Williams
Publikováno v:
New England Journal of Medicine. 338:955-962
Screening of maternal serum to identify fetuses with Down's syndrome is now routinely offered during the second trimester of pregnancy. Prenatal screening by means of serum assays or ultrasonographic measurements, either alone or in combination, may
Publikováno v:
Prenatal Diagnosis. 18:235-245
Published studies have reached varying conclusions as to the benefit of replacing human chorionic gonadotropin (hCG) measurements with the free β-subunit of hCG (the free β-subunit) for Down syndrome screening. One study reports 14 per cent higher
Publikováno v:
American Journal of Obstetrics and Gynecology. 176:1046-1051
OBJECTIVE: Our goal was to determine the status of prenatal Down syndrome screening in the United States in 1995. STUDY DESIGN: Information was sought via questionnaire from laboratories participating in external proficiency testing. RESULTS: Service
Publikováno v:
Archives of pathologylaboratory medicine. 137(7)
Context.—Participants in a College of American Pathologists external proficiency testing program for first and second trimester Down syndrome screening.Objectives.—To determine the number of women screened for Down syndrome in the United States,
Publikováno v:
Prenatal Diagnosis. 16:1115-1119
This study examines the relationship between maternal weight and serum levels of alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotropin in a population of 47,585 women being provided with prenatal screening for Down's syndrome and